In rare disease and specialty pharma, launch is only the beginning. Sustained growth often depends on patient activation, HCP confidence, coordinated care pathways and engagement that evolves across the critical first year.
The need for impactful and clear communication has never been greater, which is why we put Science brought to life at the heart of everything we think, feel and do.
Read moreIn rare disease and specialty pharma, launch is only the beginning. Sustained growth often depends on patient activation, HCP confidence, coordinated care pathways and engagement that evolves across the critical first year.
Medical Affairs teams are evolving into more strategic, insight-driven partners across the product lifecycle. This article explores ten key shifts shaping how teams can work more effectively, from integrated evidence generation and AI-enabled insight to omnichannel engagement and role-specific training.
Gene therapy offers huge potential—but also poses distinct communication challenges. At Cognite, we help clients overcome barriers like small HCP audiences and complex science with strategies that build trust, clarity and emotional connection. This article explores how to turn common challenges into powerful engagement opportunities.
Explore how the rare disease landscape continues to be transformed by innovations in science, drug development and connectivity.
Explore how biotechs can navigate their first commercialisation in Europe, overcoming market fragmentation, pharma giants, resource constraints and regulatory hurdles to achieve a successful launch.